November 12, 2023
1 min watch
Save
VIDEO: Syfovre demonstrates ‘increasing effects’ at 3 years in geographic atrophy
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Cedric Francois, MD, PhD, CEO of Apellis Pharmaceuticals, previews 3-year data investigating long-term treatment of geographic atrophy with Syfovre.
Results showed “increasing effects over time” with Syfovre (pegcetacoplan injection) as well as “slow downs up to 40% in the third year with multi-dosing,” Francois explained.
“This is something that we think will really be of great benefit to patients,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Francois C. Apellis. Presented at: Eyecelerator@AAO; Nov. 2, 2023; San Francisco.
Disclosures:
Francois reports being the CEO of Apellis.
Read more about